|
|
Post by sportsrancho on Jan 7, 2024 11:21:34 GMT -5
Definitely not a black-and-white thing, when the stock goes down people tend to get negative. But I am optimistic.
There’s more attention to Afrezza on social media than ever. Before we had a lot of users on Twitter. They’ve kind of dried up, couple of them still post, but the interest on LinkedIn has just exploded, and that’s partly because of Ginger. But it’s also because we’re expanding and people want to work for us, interview us, etc. Business people every day are connecting.
I had someone contact me on Facebook yesterday. That said, “OMG, I am so glad I found you guys!” ( He has a five-year-old T1 son.)
Anyway, in anticipation for the Clovis opening we’ll have radio interviews, etc. and I will keep you posted.
There’s also other interviews lined up where Bill will speak on Afrezza.
In five years, I haven’t seen Bill this optimistic. Yes, he always has a never give up attitude, but the slugging it out one step at a time, has turned into a hop skip and a jump.🌅
|
|
|
|
Post by prcgorman2 on Jan 7, 2024 12:10:45 GMT -5
I have a friend CEO who started a company from scratch with money raised largely from friends and relatives. She had been laid low by a layoff and her husband leaving and was at her wits end but had an epiphany that gave her the conviction that she saw an emerging business problem that nobody was paying attention to but was going to have severe impacts over time.
She created a small consulting firm of herself, then added a friendly and extremely brave technologist who built a system to help solve the emerging business problem. She and her technologist went on countless interviews to acquire venture capital but nothing materialized, but by dint of effort and good business results for her customers, they were able to hire a few employees and expand the business and cash flow underwrote a business loan and they expanded the business again and started to get noticed, so much so that other businesses emerged offering same/similar services: aka competition. At four or five years into the adventure, potential business partners, venture capital firms, and buyout offers began to emerge. It is the best real-world example I’ve seen of “Nothing succeeds like success”. Hopefully, Bill is starting to enjoy the same kind of increased momentum. Go VDEX!
|
|
|
|
Post by standup on Jan 8, 2024 11:18:04 GMT -5
We are just one more of Mike's sales force restructurings away from success! The sales force is only active on the Insulin Business Unit (IBU) which is not mentioned in kevinmik's list and there's a reason for that. It's currently unimportant as a source of revenue. The IBU did what it needed which is to sustain MNKD long enough to permit the successful execution of the Treprostinil Phase 1 trial and resulting UTHR deal. Mock if you want, but why do you want to? Silly me, I thought Afrezza was going to change the world of diabetes treatment. Now I hear it's irrelevant. |
|
|
|
Post by cretin11 on Jan 8, 2024 12:17:49 GMT -5
The sales force is only active on the Insulin Business Unit (IBU) which is not mentioned in kevinmik's list and there's a reason for that. It's currently unimportant as a source of revenue. The IBU did what it needed which is to sustain MNKD long enough to permit the successful execution of the Treprostinil Phase 1 trial and resulting UTHR deal. Mock if you want, but why do you want to? Silly me, I thought Afrezza was going to change the world of diabetes treatment. Now I hear it's irrelevant. It appears you're not paying proper homage to our leader's brilliance. Tsk tsk. |
|
|
|
Post by prcgorman2 on Jan 8, 2024 12:43:07 GMT -5
Nah, just need to complain about something that is more relevant, otherwise, well, you know, it just makes your comments look rude and snarky instead of pertinent and interesting.
|
|
|
|
Post by cretin11 on Jan 8, 2024 13:00:18 GMT -5
standup's posts were about yet another sales force restructuring, that seems relevant. To be fair, the oddest comment is yours that our insulin unit is "currently unimportant as a source of revenue" and it "did what it needed."
I'm with standup in that "I thought Afrezza was going to change the world of diabetes treatment" - furthermore I'm not prepared to abandon that belief. I hope whoever is in charge of decision making at MNKD in years to come is with us, and not in the camp of Afrezza "did what it needed."
|
|
|
|
Post by prcgorman2 on Jan 8, 2024 14:03:24 GMT -5
Are you enjoying yourself? You know I'm a staunch supporter of Afrezza and of MannKind and of the management. It's not a matter of whether Afrezza will ever become as important to MNKD and persons with diabetes as we hope. It's just that complaining about a salesforce restructure at this point in time prior to completion of Pediatric and pump/switch trials and results of Cipla trials is premature. The salesforce is important, but if you have to restructure, this is a better time than when you want them hitting on all cylinders after the trials, etc. You know all that of course, so I don't understand the effort to mock the CEO over the salesforce restructure, but hey, you and standup do you.
|
|
|
|
Post by longliner on Jan 8, 2024 14:14:05 GMT -5
Are you enjoying yourself? You know I'm a staunch supporter of Afrezza and of MannKind and of the management. It's not a matter of whether Afrezza will ever become as important to MNKD and persons with diabetes as we hope. It's just that complaining about a salesforce restructure at this point in time prior to completion of Pediatric and pump/switch trials and results of Cipla trials is premature. The salesforce is important, but if you have to restructure, this is a better time than when you want them hitting on all cylinders after the trials, etc. You know all that of course, so I don't understand the effort to mock the CEO over the salesforce restructure, but hey, you and standup do you. Didn't you hear? Vdex is selling so much that we no longer needed the sales force. Now if we can just get Vdex to use Liquidia's products most of this board will rejoice.  |
|
|
|
Post by sayhey24 on Jan 8, 2024 15:30:09 GMT -5
Are you enjoying yourself? You know I'm a staunch supporter of Afrezza and of MannKind and of the management. It's not a matter of whether Afrezza will ever become as important to MNKD and persons with diabetes as we hope. It's just that complaining about a salesforce restructure at this point in time prior to completion of Pediatric and pump/switch trials and results of Cipla trials is premature. The salesforce is important, but if you have to restructure, this is a better time than when you want them hitting on all cylinders after the trials, etc. You know all that of course, so I don't understand the effort to mock the CEO over the salesforce restructure, but hey, you and standup do you. If it had been me I would have layed most of them off a couple of years ago. Its not fair to keep sending them out only to get mowed down like they were crossing no-man's land right in front of MG 08s. I am going to start sounding like a broken record but the pump/switch trial will have very little impact on T1 sales. Mike has said time and again V-Go is for the T2 business so as it currently stands Cipla results near term will have little impact on sales. The kids approval won't be until 3Q2025 so there is nothing here near-term to impact sales. In fact I would argue that even after trial results from Cipla, unless we get SoC and label changes and broad based insurance coverage including $35 Medicare afrezza sales will be little changed. Getting broad based insurance as we have seen for 8 years is not coming anytime soon. We have already seen we were put in parentheses in the 2024 SoC so as long as BP has their boot on MNKD's neck I expect little change there. This leaves Mike 2 options; plod along with little need for sales reps; disrupt things and sell direct which can probably be done with a reduced sales force. Of course afrezza is the nuclear bomb of the diabetes industry and now with the cash in the bank Mike has the nuclear codes. The question is will he go nuclear? |
|
|
|
Post by caesar on Jan 8, 2024 16:28:45 GMT -5
Nuclear - Hope not.
Mike/Mannkind should sell the Insulin portion of the business, including Afrezza ASAP. Great product that cannot get traction - as simple as that. At some point it's going to become irrelevant, timing is everything, and Afrezza is going to become "old" technology with gene editing based applications replacing pills/needles & inhalers.
Sell it for $500 million, pay off all of the debt. No debt, $400 million cash, reduced headcount and a very promising pipeline that will generate way more revenue with the headwinds that Afrezza is still facing.
If they announced that on Wednesday, the PPS would fly way past $10/share. In addition, the shorts would scramble to cover a good portion of their position adding fuel the buying activity.
Afrezza is the "Ball & Chain" around Mannkind's growth potential.
|
|
|
|
Post by cretin11 on Jan 8, 2024 16:35:22 GMT -5
Would anyone pay $500 million for Afrezza?
|
|
|
|
Post by prcgorman2 on Jan 8, 2024 16:44:56 GMT -5
Gene editing and pancreas replacement using organs grown using stem cells on "scaffolding" aren't going to happen soon. I may someday need Afrezza. I'd prefer it remain in the portfolio. The PK/PD profile is unmatched and that has value.
|
|
|
|
Post by longliner on Jan 8, 2024 17:02:36 GMT -5
Would anyone pay $500 million for Afrezza? Is that what hairplug is jockeying to get it for?  |
|
|
|
Post by akemp3000 on Jan 8, 2024 17:19:21 GMT -5
Too funny. An optimism thread suggesting that after all these years the company should sell Afrezza now, just prior to pediatric approval, the head-to-head comparison results coming in and more. Oh well, guess it's good fodder for now.
|
|
|
|
Post by cretin11 on Jan 8, 2024 17:28:38 GMT -5
Gene editing and pancreas replacement using organs grown using stem cells on "scaffolding" aren't going to happen soon. I may someday need Afrezza. I'd prefer it remain in the portfolio. The PK/PD profile is unmatched and that has value. We agree on this, my hope is that Afrezza stays available to PWDs regardless of who "owns" it. I don't think anyone would pay half a billion for it now, hence my question. But i sure don't like the idea of us selling it now anyway while our sales efforts can't justify a robust price. We have results on the way, slower than hoped but might as well play those out. Then my preference would be to partner with a company capable of proper commercialization. Probably hopium but I'll partake in it. |
|
